Table 5.
Bleeding event | Betrixaban (n = 3716) | Enoxaparin (n = 3716) | Betrixaban versus Enoxaparin relative risk |
---|---|---|---|
Major bleeding | |||
Any | 0.67% | 0.57% | 1.19 (95% CI, 0.67-2.12) (P = .554) |
Gastrointestinal bleeding | 0.51% | 0.24% | |
Intracranial hemorrhage | 0.05% | 0.19% | |
Intraocular bleeding | 0% | 0.03% | |
Fatal bleeding | 0.03% | 0.03% | |
Clinically relevant nonmajor bleeding | |||
Any | 2.45% | 1.02% | 2.39 (95% CI, 1.64-3.49) (P < .001) |